Aktuellt
SENASTE
Redeye provides an initial take on Optomed’s Q4 2023 report. Sales during the quarter amounted to EUR3.7m (EUR4.0m) compared to our sales estimate of EUR4.5m. Moreover, EBIT came in at EUR-1.3m (EUR-0.9m), and the cash position at the end of the period amounted to EUR7.1m. Overall, the results were lower than our expectations. However, we note that the additional data to the FDA has been submitted, meaning we have a major event in front of us. We will provide a more in-depth update shortly, where we expect to make some downward changes to our short-term estimates.
LÄS MER
